Specialist healthcare group, Ark Therapeutics, and serious diseases therapies developer PsiOxus Therapeutics, said their partnership has successfully achieved its first milestone.
The firms have manufactured PsiOxus's colorectal cancer product, and as a result PsiOxus has initiated final pre-clinical toxicology studies of the product.
Martyn Williams, Chief Executive Officer of Ark said: "We are delighted that our early success with ColoAd1 will enable the development of this exciting product to move forward as planned and we look forward to continuing to provide full support to our partner as their programme moves into the clinic."
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The share price rose 4.69% to 3.35p by 15:17.
__
NR
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
The most influential people of 2025Here are the most influential people of 2025, from New York's mayor-elect Zohran Mamdani to Japan’s Iron Lady Sanae Takaichi
-
Millions of parents are missing out on up to £720 a year in extra pension cash – are you affected?A mum who narrowly missed out on the pension boost said she “never knew the government rule existed” and wants other parents to use it
